Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05874921 · ClinicalTrials.gov registry record
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
A clinical trial of Urothelial Carcinoma and Carcinoma, Transitional Cell, sponsored by UroGen Pharma.
- Recruiting
- Registry status
- 400
- Enrollment target
- 20
- Study locations
NCT05874921 is a study of Urothelial Carcinoma and Carcinoma, Transitional Cell that is actively recruiting participants, run by UroGen Pharma. The registered enrollment target is 400 participants, above the 234-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (71% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT05874921, a study of Urothelial Carcinoma and Carcinoma, Transitional Cell, is actively recruiting participants, sponsored by UroGen Pharma.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
Conditions Studied
Interventions
- DRUG Jelmyto (mitomycin) for pyelocalyceal solution
Study Locations (20)
Florida
- University of Florida - Gainesville
- Mount Sinai Medical Center of Florida, Inc. - Miami
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. - Tampa
New York
- The Feinstein Institutes for Medical Research - Lake Success
- NYU Grossman School of Medicine - New York
- SUNY Upstate - Syracuse
Maryland
- Chesapeake Urology - Baltimore
- Johns Hopkins Medical Center - Baltimore
Massachusetts
- Mass General Hospital (MGH) - Boston
- The Brigham and Womens Hospital - Boston
California
- Providence St. Johns Health Center - Santa Monica
Illinois
- Northwestern University - Chicago
Indiana
- Indiana University - Indianapolis
Iowa
- The State University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-11-17 |
| Est. Completion | 2028-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05874921
The ClinicalTrials.gov registry entry for NCT05874921 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 234-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (71% higher). The listed sponsor is UroGen Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Jelmyto (mitomycin) for pyelocalyceal solution is the first listed.
NCT05874921 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, New York, Maryland.
Frequently Asked Questions
What is clinical trial NCT05874921 about?
NCT05874921 is a clinical study titled "uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto". The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
What is the current status of trial NCT05874921?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2023-11-17. Estimated completion is 2028-01.
What conditions does trial NCT05874921 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Carcinoma, Transitional Cell, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter.
What interventions are being tested in trial NCT05874921?
The interventions under investigation include: Jelmyto (mitomycin) for pyelocalyceal solution (DRUG).
Who is sponsoring clinical trial NCT05874921?
This trial is sponsored by UroGen Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05874921 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
RECRUITING
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.